The Aplastic Anemia & MDS International Foundation received the hematology Innovation Impact Award for the MDS Clinical Research Consortium. Established in July 2012, the MDS Clinical Research Consortium is an unprecedented collaboration of the six largest MDS centers in the U.S. and is designed to undertake unique studies and trials to advance treatments and improve outcomes for patients with 骨髓增生异常综合征 (MDS）。 The Consortium enlists multiple MDS clinical research centers and fills a major gap in MDS-related clinical research in the 美国 by providing a new “critical mass” of patients and patient data to support the evaluation of promising new compounds, epidemiological studies, and translational studies leading to new classifications, treatments, and procedures. In this collaborative environment, enhanced by expanded access to patient data, tissue samples, and the use of a standardized patient work-up, research leading to potentially beneficial outcomes for patients is accelerated.
“Even from the earliest stages of development , we believed that the MDS Clinical Research Consortium was an innovative , game changing project that was perfectly aligned with our strategic plan. It is exciting –and humbling—to see that others are seeing it in the same way. We are very pleased and honored to be selected for this new and prestigious award. We deeply appreciate the support of the Edward P. Evans Foundation and our six Consortium partners who have made this program possible and for the hope it brings to patients and families for new treatments and a cure for MDS. “–John Huber, Executive Director, AA&MDSIF
“我们非常荣幸和高兴能获得ESTA殊荣。 Celgene公司和我们感谢评奖委员会对精神错乱的我国优秀的框架的肺癌筛查和持续照顾救生影响。这意味着这么多的员工，卓越的100个多名筛选中心下面的框架和最重要的是，对于那些确诊的个体或有患肺癌的风险。这是一个值得骄傲的时刻，更新我们通过帮助社区，推进癌症筛查和加速research. - 劳瑞肺芬顿刘汉铨，总裁兼首席执行官，肺癌联盟拯救生命的承诺